Irinotecan sucrosofate - Merrimack/PharmaEngine

Drug Profile

Irinotecan sucrosofate - Merrimack/PharmaEngine

Alternative Names: Irinotecan liposome injection - Merrimack; MM-398; nal-IRI; Nano-irinotecan; Nanoliposomal irinotecan - Merrimack/PharmaEngine; Nanoliposomal irinotecan injection - Merrimack/PharmaEngine; Onivyde; pegylated liposomal irinotecan hydrochloride trihydrate; PEP-02

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator HERMES BioSciences
  • Developer Medica Scientia Innovation Research; Merrimack Pharmaceuticals; PharmaEngine; Shire; University of California at San Francisco
  • Class Alkaloids; Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pancreatic cancer
  • Phase II Breast cancer; Colorectal cancer; Gastric cancer
  • Phase I Glioma; Solid tumours
  • Phase Unknown Cholangiocarcinoma; Gallbladder cancer

Most Recent Events

  • 16 Mar 2017 Phase-II clinical trials in Breast cancer (Metastatic disease) in Spain (IV) (EudraCT2016-002689-30)
  • 10 Mar 2017 The Scottish Medicines Consortium does not recommend the use of irinotecan sucrosofate within NHS Scotland due to lack of justification for the cost of treatment and robust clinical data
  • 13 Feb 2017 AIO-Studien-ggGmbH, Baxalta, Institut für Klinisch-Onkologische Forschung (IKF) am Krankenhaus Nordwest GmbH and Shire plan a phase II trial for Biliary tract cancer (NCT03044587)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top